GYRE THERAPEUTICS INC (GYRE) Stock News
NASDAQ:GYRE - Nasdaq - US4037831033 - Common Stock - Currency: USD
GYRE Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Let's take a look at the stocks that are in motion in today's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials
Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biopharmaceutical company developing innovative fibrosis-focused therapies, has successfully closed a public offering, raising approximately $23 million in gross proceeds. The offering included 2,555,555 shares of common stock at $9.00 per share, with Jefferies serving as lead book-running manager and H.C. Wainwright & Co. as co-manager. The capital infusion, which follows […]
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares...
Discover the top movers in Friday's pre-market session.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock...
Thursday's after hours session: top gainers and losers
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock...
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial...
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update...
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of 54.55% and 19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CLNN
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update...
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update...